Explore /
Poster
/ Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.

Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.

Authors

Paola Zagami

UNC Lineberger Comprehensive Cancer Center/University of Milan, Chapel Hill, NC

Paola Zagami , Yara Abdou , Alexis Caroline Wardell , Allison Mary Deal , Amy Wheless , Elizabeth Claire Dees , Lisa A. Carey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Other Breast Cancer Subtypes

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1109)

DOI

10.1200/JCO.2023.41.16_suppl.1109

Abstract #

1109

Poster Bd #

330

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).

The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).

First Author: Sudpreeda Chainitikun

Poster

2020 ASCO Virtual Scientific Program

Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.

Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.

First Author: Jennifer Lee Caswell-Jin

Poster

2018 ASCO Annual Meeting

Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).

Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).

First Author: Ji-Yeon Kim

Poster

2022 ASCO Annual Meeting

A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, <em>PIK3CA-</em>mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409).

A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409).

First Author: Cristina I. Truica